Our institution has recently developed aromatic and heteroaromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide

July 16, 2024

• Title:       

  Our institution has recently developed aromatic and heteroaromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide

• Image Source:

  Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma

• Mark:

  Figure 1

• Associated context:

  Our institution has recently developed aromatic and heteroaromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide (1, BZA) (Fig. 1), which is a radiotracer already successfully used in humans for the diagnosis of malignant melanoma, as part of a targeted radionuclide therapy approach to melanoma treatment.